Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation

摘要: Drugs containing adrenocorticotropic hormone have been used as therapy for patients with nephrotic syndrome. We previously shown that and a selective agonist the melanocortin 1 receptor (MC1R) exert beneficial actions in experimental membranous nephropathy reduced proteinuria, oxidative stress, improved glomerular morphology function. Our hypothesis is MC1R activation podocytes elicits effects by promoting stress fibers maintaining podocyte viability. To test hypothesis, we cultured highly specific agonists MC1R. Podocytes were subjected to nephrotic-inducing agent puromycin aminonucleoside, downstream of on survival, antioxidant defense, cytoskeleton dynamics studied. increase response enhance intracellular signals, transduced overexpress showed promotes expression an catalase activity reduces which results dephosphorylation p190RhoGAP formation through RhoA. In addition, protect against apoptosis. Together, these mechanisms puromycin. findings strongly support MC1R-activating may therefore be useful treat syndromes commonly considered podocytopathies.